395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more

Dayspring describes a 2015 study showing that low CSF and plasma desmosterol correlate with Alzheimer's disease. Because statins all enter the brain at steady state (hydrophilic statins like rosuvastatin still penetrate, albeit more slowly), they can suppress cholesterol synthesis there. Attia has previously discussed that most RCTs show statins have neutral or slightly positive effects on cognition, but a minority of patients experience reversible 'brain fog.' Desmosterol monitoring offers a way to personalize therapy: if desmosterol is very low, one could switch to a non-statin apoB-lowering agent (ezetimibe, bempedoic acid, PCSK9 inhibitor) that cannot cross the BBB, thereby preserving brain cholesterol synthesis while maintaining cardiovascular protection.

Dayspring describes the unique lysophospholipid transport system that allows omega-3s to cross the BBB efficiently, bypassing the usual lipoprotein carriers. He notes that while RCT evidence for brain outcomes is lacking, the observational evidence is consistent with protective associations. Attia alludes to the PREDIMED primary prevention dietary trial as an example of how selecting the right population can yield positive results, implying that future trials with biomarker-enriched cohorts (e.g., APOE4 carriers with low baseline omega-3) might better demonstrate benefit. In his own practice, Attia measures omega-3 index and aims for at least 10% because, if there is no harm, the upside might be substantial.

Dayspring and Attia emphasize that in their practice they routinely check synthesis and absorption sterol markers to guide therapy. Hyperabsorbers (who over-absorb cholesterol from the gut) may respond better to ezetimibe, while hyper-synthesizers may need statins. Dayspring speculates that the anecdotal cognitive benefit seen by some neurologists (Richard Isaacson, Kelly Otis) with ezetimibe might come from both its indirect apoB-lowering and direct brain metabolite effects. Attia mentions that they prefer this low-dose combination approach, not only for cardiovascular protection but also to hedge against potential brain cholesterol oversuppression—a strategy informed by the desmosterol hypothesis.

Dayspring notes that neurologists like Isaacson and Otis have observed what they believe is cognitive benefit in some patients on ezetimibe. The Broadway trial of obicetrapib did not test ezetimibe, but dayspring suggests that future trials could include ezetimibe arms or analyze biobanked samples from prior ezetimibe trials for Alzheimer's biomarkers. Attia reiterates that even without RCT data, the risk/benefit profile of ezetimibe is so favorable that it can be used empirically in high-risk individuals.

Attia states that E3/E4 carriers have 2–3× higher Alzheimer's risk, and E4/E4 carriers 8–12×. Dayspring details how APOE4 protein alters HDL functionality, impairing cholesterol delivery and driving amyloidogenesis. The podcast repeatedly ties APOE4 to the logic behind choosing therapies that might rescue brain HDL (e.g., obicetrapib). Both Attia and Dayspring advocate knowing APOE status not as a reason for fatalism but to double down on modifiable risk factors.

Attia is optimistic because the Broadways trial's biomarker movements were statistically significant and directionally consistent. Dayspring notes that the company is planning further studies, including cognitive assessments and possibly PET imaging. Both agree that patient selection (early, high-risk, E4 carriers) and intervention timing (before widespread neurodegeneration) will be critical, analogous to how PREDIMED succeeded by enrolling a high-risk primary prevention cohort.

Tom Dayspring explains that every cell in the body can synthesize its own cholesterol, so LDLs are almost never needed for delivery. Instead, HDLs collect excess cholesterol and transfer it to LDLs due to LDL's long circulation time (3–5 days). The LDL-receptor-mediated hepatic clearance then completes RCT. This framework means that lowering LDL does not compromise cellular cholesterol supply; it simply reflects reduced need for hepatic return. This directly addresses common patient fears that very low LDL could harm cellular membranes.

During fetal development and early childhood, the brain overproduces cholesterol to support massive myelination and synaptogenesis. At age 2, a child's LDL may be 30 mg/dL yet brain growth is maximal. After age 10, neurons cease synthesis to conserve ATP and instead rely on astrocytes that produce cholesterol via the desmosterol pathway. APOE-containing HDL-like particles (brain HDLs) distribute cholesterol in the interstitial fluid. No apoB particles cross the BBB because they are too large. Hence, plasma LDL levels have zero impact on brain cholesterol homeostasis.

In the Broadway trial, obicetrapib significantly reduced apoB and non-HDL-C. A pre-specified secondary analysis examined Alzheimer's biomarkers. Statistically positive directional changes were seen in phosphorylated tau181, Aβ42/40 ratio, and neurofilament light. Mechanistically, CETP inhibition generates very large HDL particles rich in apoA1; the liver senses low apoA1 and upregulates production. The excess apoA1 can form tiny, protein-rich HDLs that cross the BBB and fuse with brain APOE HDLs, potentially rescuing the dysfunctional APOE4 particles. Dayspring and Attia note the company plans dedicated cognitive studies, though FDA approval will initially be for cardiovascular risk reduction.